These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 14735179

  • 21. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.
    Avilés A, Neri N, Huerta-Guzmán J.
    J Surg Oncol; 2002 Jun; 80(2):111-5. PubMed ID: 12173380
    [Abstract] [Full Text] [Related]

  • 22. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A, García EL, Fernández R, Gonzalez JL, Neri N, Díaz-Maqueo JC.
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [Abstract] [Full Text] [Related]

  • 23. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA, Xiros N, Papageorgiou E, Pectasides D, Economopoulos T.
    Anticancer Res; 2007 Jul; 27(2):1191-7. PubMed ID: 17465262
    [Abstract] [Full Text] [Related]

  • 24. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI.
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [Abstract] [Full Text] [Related]

  • 25. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
    Schneider T, Tóth E, Lovey J, Molnár Z, Deák B, Várady E, Csomor J, Matolcsy A, Lengyel Z, Petri K, Gaudi I, Rosta A.
    Orv Hetil; 2011 May 08; 152(19):735-42. PubMed ID: 21498163
    [Abstract] [Full Text] [Related]

  • 26. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE, Hoskins P, Klimo P, Connors JM.
    Ann Oncol; 1991 Jan 08; 2 Suppl 1():17-23. PubMed ID: 1710485
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 08; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 28. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2002 Jun 15; 94(12):3083-8. PubMed ID: 12115338
    [Abstract] [Full Text] [Related]

  • 29. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
    Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G.
    N Engl J Med; 1997 May 01; 336(18):1290-7. PubMed ID: 9113932
    [Abstract] [Full Text] [Related]

  • 30. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.
    Broccoli A, Casadei B, Stefoni V, Pellegrini C, Quirini F, Tonialini L, Morigi A, Marangon M, Argnani L, Zinzani PL.
    BMC Cancer; 2017 Apr 17; 17(1):276. PubMed ID: 28415982
    [Abstract] [Full Text] [Related]

  • 31. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J, Shpilberg O, Raanani P, Chetrit A, Ben-Bassat I.
    Leuk Res; 1998 Nov 17; 22(11):997-1002. PubMed ID: 9783801
    [Abstract] [Full Text] [Related]

  • 32. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
    Todeschini G, Ambrosetti A, Meneghini V, Pizzolo G, Menestrina F, Chilosi M, Benedetti F, Veneri D, Cetto GL, Perona G.
    J Clin Oncol; 1990 May 17; 8(5):804-8. PubMed ID: 1692089
    [Abstract] [Full Text] [Related]

  • 33. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
    Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    N Engl J Med; 2005 Mar 24; 352(12):1197-205. PubMed ID: 15788496
    [Abstract] [Full Text] [Related]

  • 34. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

  • 35. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y, Davidson T, Goshen E, Apter S, Shimoni A, Ben-Bassat I, Nagler A.
    Ann Hematol; 2014 Aug 01; 93(8):1297-304. PubMed ID: 24595734
    [Abstract] [Full Text] [Related]

  • 36. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A, García-Conde J, Alvarez-Carmona AM, León P, Maldonado J, Alcalá A, Zubizarreta A, Sancho-Tello R, Carbonell F, Contreras E, Besses C, Hernando A, Fontanillas M, Montserrat E.
    Med Clin (Barc); 1998 May 09; 110(16):601-4. PubMed ID: 9656196
    [Abstract] [Full Text] [Related]

  • 37. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S, Yu Y, Jun-Min L, Jian-Qing M, Qiu-Sheng C, Yu C, Wei-Li Z, Jian-Hua Y, Hui-Jin Z, Yan W, Li W, Shu C, Zhi-Xiang S.
    Ann Hematol; 2009 Sep 09; 88(9):863-9. PubMed ID: 19205655
    [Abstract] [Full Text] [Related]

  • 38. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec 09; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 39. [Eight-year experience in treating aggressive mediastinal large B-cell lymphomas].
    Mangasarova IaK, Magomedova AU, Kravchenko SK, Shmakov RG, Bariakh EA, Vorob'ev VI, Mar'in DS, Skidan NI, Gemdzhian ÉG, Misiurin AV, Kremenetskaia AM, Vorob'ev AI.
    Ter Arkh; 2013 Dec 09; 85(7):50-6. PubMed ID: 24137947
    [Abstract] [Full Text] [Related]

  • 40. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN, Cadman EC, Nerenberg MI, Chen M, Bertino JR, Farber LR, Prosnitz LR.
    Cancer Treat Rep; 1982 Jun 09; 66(6):1279-84. PubMed ID: 6177407
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.